- Home
- ATAI
as 05-30-2025 4:00pm EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
| Founded: | 2018 | Country: | Germany |
| Employees: | N/A | City: | BERLIN |
| Market Cap: | 282.6M | IPO Year: | 2021 |
| Target Price: | $10.50 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $2.56 | Next Earning Date: | 05-14-2025 |
| Revenue: | $1,863,000 | Revenue Growth: | 572.56% |
| Revenue Growth (this year): | 242.21% | Revenue Growth (next year): | -51.61% |
Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Apeiron Investment Group Ltd. | ATAI | 10% Owner | Mar 24 '25 | Buy | $1.40 | 1,800,000 | $2,520,000.00 | 42,369,415 | |
| Johnson Anne Nagengast | ATAI | Chief Financial Officer | Mar 21 '25 | Sell | $1.35 | 33,545 | $45,285.75 | 140,045 | |
| Kirpekar Sahil | ATAI | Chief Business Officer | Mar 21 '25 | Sell | $1.35 | 48,563 | $65,560.05 | 115,636 | |
| Rao Srinivas | ATAI | See Remarks | Mar 21 '25 | Sell | $1.35 | 75,418 | $101,814.30 | 212,942 | |
| Short Glenn Frank | ATAI | Chief Scientific Officer | Mar 21 '25 | Sell | $1.35 | 13,161 | $17,767.35 | 42,333 | |
| Craig Kevin James | ATAI | Chief Medical Officer | Mar 21 '25 | Sell | $1.35 | 11,563 | $15,610.05 | 8,437 |
Latest ATAI Life Sciences N.V. News
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
atai Life Sciences to Participate in Upcoming Investor Conferences
TipRanks
11 days ago
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies
TipRanks
11 days ago
Home Depot backs outlook as U.S. sales ticked up: Morning Buzz
GlobeNewswire
12 days ago
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
GlobeNewswire
18 days ago
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
GlobeNewswire
19 days ago
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
TipRanks
2 months ago
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
TipRanks
2 months ago
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
Compare ATAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.